• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.

作者信息

Matsumoto Kei, Ueda Hiroyuki, Tsuboi Nobuo, Yokoo Takashi

机构信息

Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, Japan.

出版信息

Clin Exp Nephrol. 2022 Dec;26(12):1242-1243. doi: 10.1007/s10157-022-02260-7. Epub 2022 Aug 1.

DOI:10.1007/s10157-022-02260-7
PMID:35913494
Abstract
摘要

相似文献

1
Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.达格列净与晚期非糖尿病慢性肾脏病患者初始肾小球滤过率下降
Clin Exp Nephrol. 2022 Dec;26(12):1242-1243. doi: 10.1007/s10157-022-02260-7. Epub 2022 Aug 1.
2
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.达格列净可使2型糖尿病合并肾功能损害患者在2年内蛋白尿减少。
Diabetologia. 2016 Sep;59(9):2036-9. doi: 10.1007/s00125-016-4017-1. Epub 2016 Jun 15.
3
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有 2 型糖尿病的慢性肾脏病患者肾功能下降速率的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4.
4
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有 2 型糖尿病的慢性肾脏病患者尿白蛋白排泄的影响：来自 DAPA-CKD 试验的预设分析。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4.
5
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有糖尿病的慢性肾脏病患者的主要不良肾脏和心血管事件的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
6
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.达格列净在伴有中度肾功能损害（慢性肾脏病 3A 期）的 2 型糖尿病患者中的疗效和安全性：DERIVE 研究。
Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10.
7
Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria.达格列净改善慢性肾脏病合并白蛋白尿患者的临床结局。
J Gen Intern Med. 2021 Sep;36(9):2915-2917. doi: 10.1007/s11606-021-06871-w. Epub 2021 Jun 14.
8
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.达格列净和预防慢性肾脏病不良结局（DAPA-CKD）随机对照试验的原理和方案。
Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282. doi: 10.1093/ndt/gfz290.
9
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.达格列净与慢性肾脏病不良结局预防（DAPA-CKD）试验：基线特征。
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234.
10
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.达格列净对 2 型糖尿病患者肾脏疾病发生和进展的影响：DECLARE-TIMI 58 随机试验分析。
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10.

引用本文的文献

1
Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy.治疗前肾小球滤过率斜率可预测达格列净在IgA肾病中的疗效。
Kidney Int Rep. 2025 Apr 30;10(7):2405-2413. doi: 10.1016/j.ekir.2025.04.042. eCollection 2025 Jul.

本文引用的文献

1
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.达格列净和慢性肾脏病不良结局预防（DAPA-CKD）随机对照试验中肾功能突然下降发生率的预先指定分析。
Kidney Int. 2022 Jan;101(1):174-184. doi: 10.1016/j.kint.2021.09.005. Epub 2021 Sep 22.
2
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.用于非糖尿病肾病的钠-葡萄糖协同转运蛋白2抑制剂：治疗慢性肾脏病且能改善血糖水平的药物。
Clin Kidney J. 2020 Oct 9;13(5):728-733. doi: 10.1093/ckj/sfaa198. eCollection 2020 Oct.
3
Dapagliflozin in Patients with Chronic Kidney Disease.
达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.